Q2 FY2026 EarningsQ2 FY2026 results showed a GAAP EPS of -$0.02, significantly beating the consensus estimate of -$0.12. While revenue remained at zero as expected for a clinical-stage biotech, the operating loss of -$5.9M was slightly wider than the -$5.8M EBIT consensus due to a 176% YoY surge in R&D expenses. A $15.3M financing completed in July extends the cash runway into Q1 2027, supporting upcoming BPD Type 2b regulatory milestones for ABP-450.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: AEON Biopharma, Inc.(AEON) the EBIT is -5.919 M (-36.45%), Miss estimate;the EPS is -0.02 (--%), Beat estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
Revenue
TBA--
0.00B--
----
EBITMiss expectations
-0.01B36.45%
-0.01B33.13%
-0.00B3.32%
EPSExceed expectations
-0.02--
-0.12--
+0.1000--%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf